Evotec SE Reports 2023 Financials and Updates

Ticker: EVOTF · Form: 6-K · Filed: Apr 24, 2024 · CIK: 1412558

Evotec Se 6-K Filing Summary
FieldDetail
CompanyEvotec Se (EVOTF)
Form Type6-K
Filed DateApr 24, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: financial-results, corporate-update, sec-filing

TL;DR

Evotec SE dropped its 2023 year-end financials on 4/24/24. Check it out.

AI Summary

Evotec SE reported its financial results for the fiscal year ended December 31, 2023, on April 24, 2024. The company, previously known as Evotec AG, is headquartered in Hamburg, Germany, and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing provides investors with a crucial update on Evotec SE's financial performance and corporate activities for the past fiscal year, aiding in investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing (6-K) and does not contain new material risks or significant negative developments.

Key Players & Entities

  • Evotec SE (company) — Registrant
  • Evotec AG (company) — Former company name
  • April 24, 2024 (date) — Date of report
  • December 31, 2023 (date) — Fiscal year end
  • Hamburg, Germany (location) — Company headquarters

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report financial results and corporate updates for the fiscal year ended December 31, 2023, and to announce prior information.

When did Evotec SE file this report?

Evotec SE filed this report on April 24, 2024.

What was Evotec SE's former company name?

Evotec SE's former company name was Evotec AG.

Where is Evotec SE's principal executive office located?

Evotec SE's principal executive office is located at Essener Bogen 7, 22419 Hamburg, Germany.

What is Evotec SE's Standard Industrial Classification code?

Evotec SE's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 276 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-04-24 13:22:40

Filing Documents

From the Filing

evo_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant's name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F: Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7): On April 24, 2024, Evotec SE (the "Company") reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to focus on profitable growth. The press release is attached hereto as Exhibit 99.1. An accompanying investor presentation is attached hereto as Exhibit 99.2. Evotec's Annual Report 2023 is attached hereto as Exhibit 99.3. 2 SIGNATURE Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Evotec SE By: /s/ Laetitia Rouxel Name: Laetitia Rouxel Title: Chief Financial Officer Date: April 24, 2024 3 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth 99.2 Evotec SE: Resetting for profitable growth 99.3 Evotec SE: Annual Report 2023 – Shaping medicines that matter 4

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.